July outcomes disappoint but committee appears to relent on risk share arrangement

At its July meeting, the Pharmaceutical Benefits Advisory Committee disappointed stakeholders with outcomes on RSV vaccines and contraceptives but appears to have relented on a risk-sharing arrangement in response to a company's delisting request. …